$1.86 Billion is the total value of EcoR1 Capital, LLC's 67 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 68.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KURA | Sell | KURA ONCOLOGY INC | $57,907,000 | -59.0% | 1,773,037 | -61.5% | 3.11% | -69.1% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $44,030,000 | -5.0% | 3,122,704 | -19.2% | 2.37% | -28.4% |
| GERN | Sell | GERON CORP | $30,114,000 | -10.0% | 18,939,925 | -1.5% | 1.62% | -32.1% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $9,768,000 | +148.2% | 1,509,812 | -1.4% | 0.52% | +86.8% |
| CYCN | Sell | CYCLERION THERAPEUTICS INC | $4,915,000 | -70.5% | 1,606,276 | -41.4% | 0.26% | -77.8% |
| STRO | Sell | SUTRO BIOPHARMA INC | $2,028,000 | -93.5% | 93,416 | -97.0% | 0.11% | -95.1% |
| SURF | Sell | SURFACE ONCOLOGY INC | $449,000 | -98.0% | 48,558 | -98.5% | 0.02% | -98.5% |
| SVRA | Exit | SAVARA INC | $0 | – | -56,500 | -100.0% | -0.00% | – |
| XOMA | Exit | XOMA CORP DEL | $0 | – | -50,809 | -100.0% | -0.07% | – |
| UBX | Exit | UNITY BIOTECHNOLOGY INC | $0 | – | -296,000 | -100.0% | -0.07% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -379,945 | -100.0% | -0.13% | – |
| XCUR | Exit | EXICURE INC | $0 | – | -1,017,801 | -100.0% | -0.13% | – |
| RPRX | Exit | ROYALTY PHARMA PLC | $0 | – | -50,000 | -100.0% | -0.15% | – |
| GLYC | Exit | GLYCOMIMETICS INCcall | $0 | – | -850,000 | -100.0% | -0.19% | – |
| FSDC | Exit | FS DEV CORP | $0 | – | -350,000 | -100.0% | -0.28% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INCcall | $0 | – | -500,000 | -100.0% | -0.32% | – |
| DFHTU | Exit | DEERFIELD HEALTHCARE TECH ACunit 07/16/2025 | $0 | – | -500,000 | -100.0% | -0.38% | – |
| LSAC | Exit | LIFESCI ACQUISITION CORP*w exp 02/14/202 | $0 | – | -630,505 | -100.0% | -0.56% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS Icall | $0 | – | -400,000 | -100.0% | -0.58% | – |
| GLYC | Exit | GLYCOMIMETICS INC | $0 | – | -3,725,150 | -100.0% | -0.82% | – |
| Exit | GOSSAMER BIO INCnote | $0 | – | -30,000,000 | -100.0% | -2.21% | – | |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -2,548,382 | -100.0% | -2.99% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.